Pages that link to "Q59151059"

The following pages link to Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir Monotherapy (Q59151059):

Displaying 36 items.

• HIV reservoirs and immune surveillance evasion cause the failure of structured treatment interruptions: a computational study (Q28482710) (← links)
• Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens (Q28550153) (← links)
• Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice (Q28553066) (← links)
• Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study (Q33897898) (← links)
• Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks (Q34358418) (← links)
• Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial). (Q34562253) (← links)
• Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection (Q34638302) (← links)
• Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in Ghana (Q35914071) (← links)
• Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients (Q36278470) (← links)
• Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients (Q36426953) (← links)
• Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting (Q36722728) (← links)
• Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4 T-cells Over Time (Q37057964) (← links)
• Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. (Q37582477) (← links)
• Protease inhibitor monotherapy: what is its role? (Q37987855) (← links)
• Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods (Q38086335) (← links)
• Switch strategies in antiretroviral therapy regimens (Q38235295) (← links)
• Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial (Q38883681) (← links)
• Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications (Q38936786) (← links)
• Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial (Q39024445) (← links)
• Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy. (Q39178197) (← links)
• Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals (Q40060728) (← links)
• Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. (Q40458885) (← links)
• A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy (Q40724324) (← links)
• Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy. (Q40873579) (← links)
• Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA. (Q41451817) (← links)
• Monotherapy with boosted PIs as an ART simplification strategy in clinical practice (Q41590736) (← links)
• Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start (Q42229844) (← links)
• Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study (Q43572711) (← links)
• Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial (Q44697091) (← links)
• Dolutegravir monotherapy as maintenance ART bites the dust. (Q46731216) (← links)
• Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. (Q47589443) (← links)
• Dolutegravir plus lamivudine maintain HIV-1 suppression through week 48 in a pilot randomized trial. (Q52732480) (← links)
• Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy (Q57063852) (← links)
• In-depth validation of total HIV-1 DNA assays for quantification of various HIV-1 subtypes (Q59328843) (← links)
• The tide cannot be turned without us: sex workers and the global response to HIV (Q87338644) (← links)
• HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial (Q91862873) (← links)